Vtv Therapeutics Inc (VTVT)

Jan 17, 2025

7MM Type 1 Diabetes Market Drug Forecast and Market Analysis 2023-2024 & 2033: Value to Reach $9.91 Billion - GlobeNewswire Inc.

Jan 17, 2025

Jan 13, 2025

vTv Therapeutics Highlights Progress on Diabetes Treatment - TipRanks

Jan 13, 2025

Jan 10, 2025

vTv Therapeutics (NASDAQ:VTVT) Stock Quotes, Forecast and News Summary - Benzinga

Jan 10, 2025

Jan 09, 2025

(VTVT) Investment Analysis - Stock Traders Daily

Jan 09, 2025

Dec 29, 2024

Trend Tracker for (VTVT) - Stock Traders Daily

Dec 29, 2024

Dec 18, 2024

Where are the Opportunities in (VTVT) - Stock Traders Daily

Dec 18, 2024

Dec 15, 2024

Fmr LLC Takes $2.40 Million Position in vTv Therapeutics Inc. (NASDAQ:VTVT) - Defense World

Dec 15, 2024

Dec 15, 2024

vTv Therapeutics Inc. (NASDAQ:VTVT) Short Interest Update - Defense World

Dec 15, 2024

Dec 15, 2024

Vimeo, Inc. (NASDAQ:VMEO) Sees Significant Increase in Short Interest - Defense World

Dec 15, 2024

Dec 10, 2024

vTv Therapeutics (NASDAQ:VTVT) Coverage Initiated by Analysts at Alliance Global Partners - Defense World

Dec 10, 2024

Dec 10, 2024

Alliance Global Partners Initiates Coverage of vTv Therapeutics (VTVT) with Buy Recommendation - MSN

Dec 10, 2024

Dec 09, 2024

CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF BRAIN METASTASIS FROM BREAST CANCER - The Malaysian Reserve

Dec 09, 2024

Dec 09, 2024

Cantex Scores Third FDA Orphan Drug Win for Breakthrough Breast Cancer Brain Metastasis Treatment - StockTitan

Dec 09, 2024

Dec 08, 2024

(VTVT) Long Term Investment Analysis - Stock Traders Daily

Dec 08, 2024

Dec 03, 2024

vTv Therapeutics (FRA:5VT0) EBITDA : €-20.38 Mil (TTM As of Sep. 2024) - GuruFocus.com

Dec 03, 2024

Dec 02, 2024

vTv Therapeutics to Participate in 7th Annual Evercore HealthCONx Conference - The Manila Times

Dec 02, 2024

Dec 02, 2024

vTv Therapeutics to Present at Evercore HealthCONx Conference in December 2024 - StockTitan

Dec 02, 2024

Dec 01, 2024

vTv Therapeutics (STU:5VT0) Shares Outstanding (EOP) : 2.61 Mil (As of Sep. 2024) - GuruFocus.com

Dec 01, 2024

Nov 25, 2024

vTv Therapeutics (STU:5VT0) Operating Cash Flow per Share : €-4.95 (TTM As of Sep. 2024) - GuruFocus.com

Nov 25, 2024

Nov 25, 2024

vTv Therapeutics (STU:5VT0) Net Issuance of Preferred Stock : €0.00 Mil (TTM As of Sep. 2024) - GuruFocus.com

Nov 25, 2024

Nov 25, 2024

vTv Therapeutics (STU:5VT0) Change In Receivables : €-0.12 Mil (TTM As of Sep. 2024) - GuruFocus.com

Nov 25, 2024

Nov 25, 2024

vTv Therapeutics (STU:5VT0) Total Inventories : €0.00 Mil (As of Sep. 2024) - GuruFocus.com

Nov 25, 2024

Nov 25, 2024

vTv Therapeutics (STU:5VT0) Cash Flow from Financing : €48.09 Mil (TTM As of Sep. 2024) - GuruFocus.com

Nov 25, 2024

Nov 23, 2024

VTv Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 23, 2024

Nov 21, 2024

Bluejay Therapeutics Announces Expansion of Leadership Team and Board of Directors - GlobeNewswire

Nov 21, 2024

Nov 20, 2024

Insider Buying: Paul Sekhri Acquires Shares of vTv Therapeutics Inc (VTVT) - GuruFocus.com

Nov 20, 2024

Nov 19, 2024

vTv therapeutics CEO Paul Sekhri buys $83,811 in stock - Investing.com

Nov 19, 2024

Nov 17, 2024

vTv Therapeutics (NASDAQ:VTVT) shareholders are up 29% this past week, but still in the red over the last five years - Simply Wall St

Nov 17, 2024

Nov 17, 2024

vTv Therapeutics (NASDAQ:VTVT) adds US$9.5m to market cap in the past 7 days, though investors from five years ago are still down 71% - Yahoo Finance

Nov 17, 2024

Nov 16, 2024

Objective long/short (VTVT) Report - Stock Traders Daily

Nov 16, 2024

Nov 13, 2024

vTv Therapeutics (FRA:5VT0) 5-Year EBITDA Growth Rate : 25.50% (As of Jun. 2024) - GuruFocus.com

Nov 13, 2024

Nov 13, 2024

VTv Therapeutics: Q3 Earnings Snapshot - Darien Times

Nov 13, 2024

Nov 13, 2024

NeuroPace Reports Third Quarter 2024 Financial Results and Increases 2024 Revenue Guidance - The Manila Times

Nov 13, 2024

Nov 12, 2024

vTv Therapeutics Announces 2024 Third Quarter Financial Results and Provides Corporate Update - GlobeNewswire

Nov 12, 2024

Oct 26, 2024

vTv Therapeutics Faces License Agreement Termination - Yahoo Finance

Oct 26, 2024

Oct 26, 2024

How the (VTVT) price action is used to our Advantage - Stock Traders Daily

Oct 26, 2024

Oct 25, 2024

VTv, OnKure Terminate Cellular Drug Licensing Agreement - MarketWatch

Oct 25, 2024

Oct 25, 2024

vTv Therapeutics ends key license agreement with OnKure - Investing.com

Oct 25, 2024

Oct 25, 2024

VTv Therapeutics : Termination of Material Agreement Form 8 K - Marketscreener.com

Oct 25, 2024

Oct 21, 2024

VTv Therapeutics: Q2 Earnings Snapshot - Barchart

Oct 21, 2024

Oct 21, 2024

Alzheimer's disease Market Size in the 7MM was ~USD 3,500 Million in 2022 | DelveInsight - openPR

Oct 21, 2024

Oct 15, 2024

Trading (VTVT) With Integrated Risk Controls - Stock Traders Daily

Oct 15, 2024

Oct 04, 2024

Resolution names Paul Sekhri chair - BioCentury

Oct 04, 2024

Oct 03, 2024

Alzheimer’s disease Treatment Market Size in the 7MM was ~USD 3,500 Million in 2022, estimated DelveInsight - Barchart

Oct 03, 2024

Oct 01, 2024

Alzheimer’s Disease Treatment Market Trends As Discussed In New Market Research Report - WhaTech

Oct 01, 2024